EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access

Review Article: GLP ‐1 Receptor Agonists and Glucagon/ GIP / GLP ‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD

Maryam Zafer, Federica Tavaglione iD, Manuel Romero-Gómez iD, Rohit Loomba iD

Alimentary Pharmacology & Therapeutics · 2025-06 · 61 (12) · 1872-1888

DOI: 10.1111/apt.70196 ↗

At a glance

Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, published online on 2025-05-13. Written by Maryam Zafer and 3 co-authors. Institution: MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Non-alcoholic Fatty Liver Disease, Gastric Inhibitory Polypeptide, Receptors, Gastrointestinal Hormone. Cited 51 times so far (Crossref); 137 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, John C. Martin Foundation, NCATS NIH HHS.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is primarily managed through diet and lifestyle modifications. However, these behavioural interventions alone may not achieve disease regression or remission, and maintaining long‐term adherence is challenging. Incretin mimetics and other gastrointestinal hormones targeting the pleiotropic pathophysiological pathways underlying MASLD have now emerged as promising disease‐modifying therapies.

Aims

This is a comprehensive review summarising the role of glucagon‐like peptide‐1 (GLP‐1) receptor agonists and glucagon/glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor dual or triple agonists in the treatment of metabolic dysfunction‐associated steatohepatitis (MASH).

Methods

Only clinical trials with endpoints assessed by liver histology were included for a robust evaluation of therapeutic efficacy.

Results

Recent evidence from phase 2 clinical trials for MASH demonstrated that pharmacological agents based on GLP‐1 receptor agonism are effective in improving disease activity. Additionally, tirzepatide and survodutide showed potential clinical benefits in reducing fibrosis. Other cardiometabolic benefits observed include weight loss and improvements in glycaemic control and lipid profile. Adherence to treatment may be limited by gastrointestinal side effects, though they were found to be generally mild to moderate in severity. An interim analysis of the semaglutide phase 3 trial confirmed its efficacy in improving steatohepatitis and demonstrated its potential to improve fibrosis.

Conclusions

GLP‐1 receptor agonists, alone or in combination with GIP and/or glucagon receptor agonists, represent promising, effective pharmacotherapies for the treatment of MASLD/MASH. Larger and longer‐duration clinical trials are needed to further evaluate the efficacy and safety of GIP receptor and glucagon receptor agonism.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsNon-alcoholic Fatty Liver DiseaseGastric Inhibitory PolypeptideReceptors, Gastrointestinal HormoneHumansGlucagon-Like Peptide-1 ReceptorReceptors, Glucagon

Author keywords

GLP‐1MASHNAFLD/MASLDhepatology

Substances

Glucagon-Like Peptide-1 Receptor AgonistsGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 ReceptorReceptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorReceptors, Glucagon

Authors and institutions

  • MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • UCM Digestive Diseases and Ciberehd, Virgen Del Rocío University Hospital, Institute of Biomedicine of Seville (CSIC/HUVR/US), University of Seville, Seville, Spain.
  • School of Public Health, University of California at San Diego, La Jolla, California, USA.

ORCID profiles: Federica Tavaglione, Manuel Romero-Gómez, Rohit Loomba

Funding

  • NIDDK NIH HHS
  • John C. Martin Foundation
  • NCATS NIH HHS
  • NIAAA NIH HHS
  • NHLBI NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Heart, Lung, and Blood Institute

Cite

APA

Zafer, M., Tavaglione, F., Romero-Gómez, M., & Loomba, R. (2025). Review Article: GLP ‐1 Receptor Agonists and Glucagon/ GIP / GLP ‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Alimentary Pharmacology & Therapeutics, 61(12), 1872-1888. https://doi.org/10.1111/apt.70196

Vancouver

Zafer M, Tavaglione F, Romero-Gómez M, Loomba R. Review Article: GLP ‐1 Receptor Agonists and Glucagon/ GIP / GLP ‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Alimentary Pharmacology & Therapeutics. 2025;61(12):1872-1888. doi:10.1111/apt.70196

BibTeX
@article{Zafer2025,
  author = {Zafer, Maryam and Tavaglione, Federica and Romero-Gómez, Manuel and Loomba, Rohit},
  title = {Review Article: GLP ‐1 Receptor Agonists and Glucagon/ GIP / GLP ‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {12},
  pages = {1872--1888},
  doi = {10.1111/apt.70196}
}
Start for free →